LTFS
CBIO

Ladenburg Thalmann Financial Services’s Crescent Biopharma CBIO Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10
Closed -$5.13K – 4729
2015
Q4 		$6K Hold
10
– – ﹤0.01% 3959
2015
Q3 		$6K Buy
+10
New +$7.22K ﹤0.01% 3827

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CBIO Position: Q1 2016 in Review

Ladenburg Thalmann Financial Services sold out of Crescent Biopharma (CBIO) in Q1 2016, closing a stake of 10 shares — an estimated $5.13K sold.

Ladenburg Thalmann Financial Services first reported a position in CBIO in Q3 2015 and held it in 2 quarters. The position peaked at $6K in Q4 2015. 30 funds tracked by Wall St. Rank hold CBIO as of Q1 2016.

  • Ladenburg Thalmann Financial Services reported no remaining Crescent Biopharma position as of Q1 2016 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 10 Crescent Biopharma shares in Q1 2016, an estimated $5.13K.
  • Ladenburg Thalmann Financial Services first reported a position in Crescent Biopharma in Q3 2015 and held it in 2 quarters.
  • Ladenburg Thalmann Financial Services's Crescent Biopharma position peaked at $6K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2016.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2016, filed 16 May 2016.